(Reuters) - With priority review status, the U.S. Food and Drug
Administration will make its decision on whether to approve the
additional use of the drug by teenagers within six months,
rather than the usual 10- to 12-month review period.
The agency generally grants priority review to products
that are considered to be potentially significant therapeutic
advancements over existing therapies.
Read more at Reuters.com Government Filings News
Administration will make its decision on whether to approve the
additional use of the drug by teenagers within six months,
rather than the usual 10- to 12-month review period.
The agency generally grants priority review to products
that are considered to be potentially significant therapeutic
advancements over existing therapies.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment